Ysios Capital — 2015 Investments

1 investments dated 2015 · listed companies and verified rows first · show all

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURASeries B · Mar 2015 · $21M

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life Sciences Chiesi Ventures Columbus Venture Partners Droia Ventures Foresite Capital Jazzya Investments +6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.